{"entity":{"id":"innocare","kind":"company","name":"InnoCare Pharma","aka":["诺诚健华"],"tldr":"InnoCare developed orelabrutinib, a selective BTK-blocking pill approved in China for chronic lymphocytic leukaemia and mantle cell and marginal zone lymphomas.","summary":"InnoCare Pharma, based in Beijing, founded in 2015 and listed as 9969.HK and 688428.SS, developed orelabrutinib, a selective BTK-blocking tablet approved in China for chronic lymphocytic leukaemia and for mantle cell and marginal zone lymphomas. Orelabrutinib, sold as Yinuokai, was approved in 2020 and 2023, and the pipeline includes the pan-TRK inhibitor zurletrectinib, the BCL2 inhibitor mesutoclax, the CD20 by CD3 bispecific ICP-B02 and a TYK2 programme; the company was co-founded by Jisong Cui and the structural biologist Yigong Shi. OnCo links it to BTK as a target and to the orelabrutinib record. Whether a selective BTK inhibitor can differentiate from rival BTK inhibitors in the same domestic market is the open question. Orelabrutinib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.innocarepharma.com/en"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":["btk"],"drugs":["orelabrutinib","icp-248"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06363994","nct04685226","nct07617493","nct05678270","nct05745623","nct04014205","nct07082686","nct06082102"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.innocarepharma.com/en","ticker":"9969.HK / 688428.SS","founded":2015,"investors":[],"funding":[]},"route":"/companies/innocare/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"}],"drug":[{"id":"icp-248","kind":"drug","name":"ICP-248","route":"/drugs/icp-248/"},{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/"}],"trial":[{"id":"nct06363994","kind":"trial","name":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","route":"/trials/nct06363994/"},{"id":"nct04685226","kind":"trial","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","route":"/trials/nct04685226/"},{"id":"nct05678270","kind":"trial","name":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","route":"/trials/nct05678270/"},{"id":"nct04014205","kind":"trial","name":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","route":"/trials/nct04014205/"},{"id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","route":"/trials/nct07082686/"},{"id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","route":"/trials/nct06082102/"},{"id":"nct07617493","kind":"trial","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","route":"/trials/nct07617493/"},{"id":"apex-03","kind":"trial","name":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","route":"/trials/apex-03/"},{"id":"nct05745623","kind":"trial","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","route":"/trials/nct05745623/"}]}}